FibroBiologics Inc
Filed Jun 18, 2024.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Jun 18, 2024
Contents
CAPITALIZATION
The following table sets forth our cash and cash equivalents and capitalization as of March 31, 2024 (unaudited), as follows.
| ● | on an actual basis; and |
| ● | on an as adjusted basis to give effect to the 16,022,644 shares of common stock that we may sell to GEM pursuant to the GEM SPA that are being registered in this registration statement at an assumed offering price of $6.06 per share, after deducting estimated offering expenses payable by us. |
This table should be read in conjunction with, and is qualified in its entirety by reference to, our financial statements and related notes incorporated by reference into this prospectus.
| Actual | As Adjusted | |
|---|---|---|
| (in thousands, except for share and per share amounts) | ||
| Cash and cash equivalents | $8,158 | $105,131 |
| Stockholders’ equity: | ||
| Preferred Stock, $0.00001 par value per share; 8,750,000 Series A Preferred shares authorized, actual and as adjusted; no Series A Preferred shares issued and outstanding, actual and as adjusted | — | — |
| Preferred Stock, $0.00001 par value per share; 5,000,000 Series B Preferred shares authorized, actual and as adjusted; no Series B Preferred shares issued and outstanding, actual and as adjusted | — | — |
| Preferred Stock, $0.00001 par value per share; 5,000,000 Series B-1 Preferred shares authorized, actual and as adjusted; no Series B-1 Preferred shares issued and outstanding, actual and as adjusted | — | — |
| Preferred Stock, $0.00001 par value per share; 2,500 Series C Preferred shares authorized, issued and outstanding, actual and as adjusted | — | — |
| Non-voting Common stock, $0.00001 par value per share; 30,000,000 shares authorized, actual and as adjusted; no shares issued and outstanding, actual and as adjusted | — | — |
| Voting Common Stock, $0.00001 par value per share; 100,000,000 shares authorized, actual and as adjusted; 32,719,125 shares issued and outstanding, actual; 48,741,769 shares issued and outstanding, as adjusted | — | — |
| Additional paid-in capital | 28,954 | 136,710 |
| Accumulated deficit | (32,817) | (43,600) |
| Total stockholders’ equity/(deficit) | $(3,863) | $93,110 |
| Total capitalization | $(3,863) | $93,110 |
The number of shares of our voting common stock reflected in our actual and as adjusted information set forth in the table above excludes:
| ● | 4,005,375 shares of common stock issuable upon exercise of stock options outstanding under our 2022 Stock Plan (as defined herein) as of March 31, 2024; |
| ● | 8,494,625 shares of common stock reserved for issuance under our 2022 Stock Plan; |
| ● | 10,321 shares of common stock underlying warrants that were issued in connection with the issuance of certain shares of the Series B-1 Preferred Stock; and |
| ● | 1,299,783 shares of common stock underlying warrants to purchase common stock that were issued to GYBL upon the Direct Listing pursuant to the GEM SPA. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.